Serko and Napier Port rallied on small earnings beats.
Asian markets were mixed as the AI tailwind subsided, and the Middle East conflict continued.
Chair Bridget Coates says the NZX-listed honey company is in the strongest position it’s been for some time.
F&P Healthcare and Ebos were caught in the souring on Aussie health stocks.
The listed cancer diagnostic company must raise $24 million, in a bid to survive.
Biotech giant's shares plunge 21% at market open on the ASX.
The cancer diagnostics company has reined in its cash burn until Medicare reimbursement of its US tests is resumed.
The space company’s quarterly revenue hit US$200m as net loss fell from US$60.6m to US$45m year on year.
Gentrack seeks to calm naysayers, clawing back some losses.
Briscoe Group boss Rod Duke says subleasing existing spaces instead is ‘way less risk, for greater return’.